<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01287845</url>
  </required_header>
  <id_info>
    <org_study_id>15117</org_study_id>
    <secondary_id>2010-022031-11</secondary_id>
    <nct_id>NCT01287845</nct_id>
  </id_info>
  <brief_title>PET/CT (Positron Emission Tomography/Computed Tomography) Imaging for Safety and Tolerability and Diagnostic Performance of BAY1075553 in Patients With Prostate Cancer and Healthy Volunteers</brief_title>
  <official_title>Open-label, Multi Center PET/CT Study for Investigation of Safety, Tolerability, Biodistribution and Diagnostic Performance of the 18F Labeled PET Tracer BAY1075553 Following a Single Intravenous Administration of 300 MBq in Patients With Prostate Cancer as Well as Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability of the Tracer in PET/CT in Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Life Molecular Imaging SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Life Molecular Imaging SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PET/CT imaging study for evaluation of safety and tolerability and diagnostic performance of&#xD;
      BAY1075553 in patients with prostate cancer and in healthy volunteers&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety parameters, for example laboratory and electrocardiogram abnormalities</measure>
    <time_frame>Day 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Effective radiation dose given in mSv (milliSievert) in healthy volunteers</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall lesion detection rate</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion detection rate in comparison to histology, where available (cancer lesion detection rate)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion detection rate in comparison to MRI (Magnetic Resonance Imaging) and/or [11C] (11Carbon)- or [18F] (18Fluor)-choline PET/CT (whenever available)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation score in all lesions identified with BAY1075553</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Diagnostic Imaging</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1075553</intervention_name>
    <description>Cancer patients, single intravenous bolus injection of 300 MBq BAY1075553 over 60 seconds on the treatment day 1</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1075553</intervention_name>
    <description>Healthy volunteers for dosimetry, single intravenous bolus injection of 300 MBq BAY1075553 over 60 seconds on the treatment day 1</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Part 1: Healthy volunteers only&#xD;
&#xD;
             -- Males ≥ 40 years of age&#xD;
&#xD;
          -  Part 2: Prostate cancer patients&#xD;
&#xD;
               -  Males ≥ 18 years of age&#xD;
&#xD;
               -  Serum PSA (Prostate-Specific Antigen) value above normal.&#xD;
&#xD;
               -  Patients had an MRI and/or a positive [11C] - or [18F] -choline PET/CT for&#xD;
                  primary diagnosis (Note: MRI and [11C]-or [18F]-choline PET/CT are optional for&#xD;
                  primary prostate cancer patients) or recurrence detection of prostate cancer and&#xD;
                  the primary cancer disease (adenocarcinoma) is histologically confirmed&#xD;
&#xD;
               -  Patients with primary prostate cancer have to be scheduled for prostatectomy&#xD;
&#xD;
               -  In patients with primary prostate cancer, histopathological evaluation has to&#xD;
                  show an adenocarcinoma with a Gleason score of 3 + 3 or higher in at least two&#xD;
                  biopsies at any location in the prostate&#xD;
&#xD;
               -  Patients with advanced primary or recurrent prostate cancer and a high likelihood&#xD;
                  to display lymph node metastasis, ideally scheduled for explorative pelvic&#xD;
                  lymphadenectomy, are to be preferably included&#xD;
&#xD;
          -  Part 3: Prostate cancer patients -- The criteria for eligibility of part 3 are&#xD;
             identical to the ones of part 2. Except it is now no longer a preference but mandatory&#xD;
             to only enrol patients with a presumably high likelihood of metastatic disease,&#xD;
             especially lymph node metastasis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent severe and/or uncontrolled and/or unstable medical disease other than&#xD;
             prostate cancer (e.g. poorly controlled diabetes, congestive heart failure, myocardial&#xD;
             infarction within 12 months prior to planned injection of BAY1075553, unstable and&#xD;
             uncontrolled hypertension, chronic renal or hepatic disease, severe pulmonary disease)&#xD;
             which could compromise participation in the study&#xD;
&#xD;
          -  Acute renal insufficiency of any intensity, either due to hepato-renal syndrome or&#xD;
             occurring in the peri-operative liver transplantation period&#xD;
&#xD;
          -  Active inflammatory bowel disease within the last 6 months&#xD;
&#xD;
          -  Acute prostatitis requiring medical treatment within the last 6 months&#xD;
&#xD;
          -  A non-urologic bacterial infection requiring active treatment with antibiotics within&#xD;
             3 months&#xD;
&#xD;
          -  Active other malignancy (except basal cell or squamous cell skin cancer) within the&#xD;
             last 2 years&#xD;
&#xD;
          -  Patients with primary prostate cancer only: androgen ablation within 3 months before&#xD;
             planned treatment&#xD;
&#xD;
          -  Subject fulfils criteria which in the opinion of the investigator preclude&#xD;
             participation for scientific reasons, for reasons of compliance, or for reasons of the&#xD;
             subject's safety&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Linz</city>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>January 31, 2011</study_first_submitted>
  <study_first_submitted_qc>February 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2011</study_first_posted>
  <last_update_submitted>January 18, 2013</last_update_submitted>
  <last_update_submitted_qc>January 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <keyword>Neoplasm</keyword>
  <keyword>Diagnostic Imaging</keyword>
  <keyword>PET (Positron Emission Tomography) -tracer</keyword>
  <keyword>PET-diagnosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

